Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelima Denduluri

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Drugs - Real World Outcomes|December 20, 2022
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United StatesNeelima Denduluri, Janet L Espirito, Michelle D Hackshaw, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 8, 2019
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancerJeffrey Crawford, Neelima Denduluri, Debra Patt, et al.
Cancer Biology & Therapy|December 7, 2007
Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri, Sherry X Yang, Arlene W Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
ASCO Clinical Practice Guideline Endorsements and AdaptationsManish A Shah, Thomas K Oliver, Douglas E Peterson, et al.
Journal of Clinical Pharmacology|April 16, 2026
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerZoey Tang, KyoungSoo Lim, Yu Jiang, et al.
Journal of Global Oncology|August 16, 2018
ASCO Resource-Stratified Guidelines: Methods and OpportunitiesSana Al-Sukhun, Sarah Temin, Mariana Chavez-MacGregor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2017
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority PopulationsJennifer Griggs, Shail Maingi, Victoria Blinder, et al.
Oncology|July 28, 2007
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancerMatthew L Goldman, Neelima Denduluri, Arlene W Berman, et al.
Journal of the American Geriatrics Society|August 5, 2005
Serum erythropoietin and aging: a longitudinal analysisWilliam B Ershler, Shan Sheng, Julie McKelvey, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Drugs - Real World Outcomes|December 20, 2022
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United StatesNeelima Denduluri, Janet L Espirito, Michelle D Hackshaw, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 8, 2019
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancerJeffrey Crawford, Neelima Denduluri, Debra Patt, et al.
Cancer Biology & Therapy|December 7, 2007
Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri, Sherry X Yang, Arlene W Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
ASCO Clinical Practice Guideline Endorsements and AdaptationsManish A Shah, Thomas K Oliver, Douglas E Peterson, et al.
Journal of Clinical Pharmacology|April 16, 2026
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerZoey Tang, KyoungSoo Lim, Yu Jiang, et al.
Journal of Global Oncology|August 16, 2018
ASCO Resource-Stratified Guidelines: Methods and OpportunitiesSana Al-Sukhun, Sarah Temin, Mariana Chavez-MacGregor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2017
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority PopulationsJennifer Griggs, Shail Maingi, Victoria Blinder, et al.
Oncology|July 28, 2007
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancerMatthew L Goldman, Neelima Denduluri, Arlene W Berman, et al.
Journal of the American Geriatrics Society|August 5, 2005
Serum erythropoietin and aging: a longitudinal analysisWilliam B Ershler, Shan Sheng, Julie McKelvey, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Pageof 6